𝗣𝗮𝗿𝘁 𝟭: 𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝘃𝘀. 𝗟𝗼𝗻𝗴𝘁𝗲𝗿𝗺 𝗘𝗳𝗳𝗲𝗰𝘁𝘀 In response to my advocacy for dopamine reduction therapy, I hear a common response. Levodopa (and other dopaminergic treatments) promptly restoring movement in Parkinson's in almost everyone who receives the treatment argues in support of the disease as being one of dopamine deficiency. This will be part 1
Share This Sign up at: ParkinsonsDisease.blog About Jonathan Sackner-Bernstein, MD Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD. Dr. S-B’s Linkedin page RightBrainBio, Inc. was incorporated in
Share This Sign up at: ParkinsonsDisease.blog About Jonathan Sackner-Bernstein, MD Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD. Dr. S-B’s Linkedin page RightBrainBio, Inc. was incorporated in
𝖤𝗇𝖽𝗈𝖼𝗋𝗂𝗇𝗈𝗅𝗈𝗀𝗂𝗌𝗍𝗌 𝗌𝖾𝖾 𝖽𝗂𝖺𝖻𝖾𝗍𝖾𝗌 𝗌𝗈 𝖽𝗂𝖿𝖿𝖾𝗋𝖾𝗇𝗍𝗅𝗒 𝗍𝗁𝖺𝗇 𝗇𝖾𝗎𝗋𝗈𝗅𝗈𝗀𝗂𝗌𝗍𝗌 𝗌𝖾𝖾 𝖯𝖺𝗋𝗄𝗂𝗇𝗌𝗈𝗇'𝗌. 𝖨𝗇 𝖾𝖺𝖼𝗁, 𝗍𝗋𝖾𝖺𝗍𝗆𝖾𝗇𝗍 𝗂𝗌 𝖿𝗈𝖼𝗎𝗌𝖾𝖽 𝗈𝗇 𝗋𝖾𝗉𝗅𝖺𝖼𝗂𝗇𝗀 (𝗈𝗋 𝖺𝗎𝗀𝗆𝖾𝗇𝗍𝗂𝗇𝗀 𝗍𝗁𝖾 𝖾𝖿𝖿𝖾𝖼𝗍𝗌 𝗈𝖿) 𝖺 𝗆𝗈𝗅𝖾𝖼𝗎𝗅𝖾 𝖻𝖺𝗌𝖾𝖽 𝗈𝗇 𝗍𝗁𝖾 𝗎𝗇𝖽𝖾𝗋𝗌𝗍𝖺𝗇𝖽𝗂𝗇𝗀 𝗍𝗁𝖺𝗍 𝗍𝗁𝖺𝗍 𝗆𝗈𝗅𝖾𝖼𝗎𝗅𝖾 𝗂𝗌 𝖽𝖾𝖿𝗂𝖼𝗂𝖾𝗇𝗍. 𝖨𝗍 𝗌𝖾𝖾𝗆 𝗋𝖾𝖺𝗌𝗈𝗇𝖺𝖻𝗅𝖾 𝗍𝗈 𝗏𝗂𝖾𝗐 𝗂𝗇𝗌𝗎𝗅𝗂𝗇 𝖺𝗌 𝖿𝗂𝗑𝗂𝗇𝗀 𝖽�
In 2017, Ivan asked me for help. I did not feel capable, but he was my buddy and he certainly needed help. His Parkinson's was worsening. I made a commitment to him to make Parkinson's my focus - to figure out something. And before he died,
